Commentary: Appropriate Downstaging and TACE in HCC, September 2022August 23, 2022Hepatocellular Carcinoma
Repeating TACE yields a survival benefit in intermediate-stage HCCAugust 22, 2022Hepatocellular Carcinoma
Advanced HCC with PVTT: Sorafenib+TACE more efficacious when combined with an immune checkpoint inhibitor and radiotherapyAugust 22, 2022Hepatocellular Carcinoma
HCC: Effective local tumor control with “no-touch” radiofrequency ablationAugust 22, 2022Hepatocellular Carcinoma
Better survival among children vs adults with HCC likely attributed to more aggressive surgical managementAugust 22, 2022Hepatocellular Carcinoma
Recurrent HCC: Adjuvant sorafenib after RFA offers survival benefit over RFA aloneAugust 22, 2022Hepatocellular Carcinoma
HBV-related HCC: Clinical outcomes of patients on anti-PD-1 therapy not compromised by HBV viral loadAugust 22, 2022Hepatocellular Carcinoma
Advanced HCC with PVTT: Hepatic arterial infusion more effective than transcatheter arterial chemoembolizationAugust 22, 2022Hepatocellular Carcinoma
Alcoholism and ALDH2 rs671 polymorphism in patients with HBV-related cirrhosis necessitate close monitoring for HCCAugust 22, 2022Hepatocellular Carcinoma
Liver Transplant for HCC: Long-term outcome of downstaging to within Milan criteria support national downstaging policyAugust 22, 2022Hepatocellular Carcinoma
Liver Transplant for HCC: Long-term outcome of downstaging to within Milan criteria support national downstaging policyAugust 22, 2022Hepatocellular Carcinoma
Commentary: HCC With HCV and Treatment Comparisons for Unresectable HCC, August 2022July 28, 2022Hepatocellular Carcinoma
Beta-adrenergic receptor blocker use improves overall survival in HCCJuly 27, 2022Hepatocellular Carcinoma
Lenvatinib plus IDADEB-TACE tops lenvatinib monotherapy in advanced HCCJuly 27, 2022Hepatocellular Carcinoma
